McDermott + Bull has successfully placed Chris Robillard as the Chief Business Officer at Crinetics Pharmaceuticals. Chris will develop, lead, and execute on the company’s business development strategy. He will build global pharmaceutical alliances to maximize the value of Crinetics Pharmaceuticals’ programs and international expansion.

Chris brings over a decade of experience developing and implementing corporate development strategies to capitalize on growth opportunities for biopharmaceutical companies. Before joining Crinetics Pharmaceuticals, he was the Vice President and Head of Business Development for Goldfinch Bio. Prior to Goldfinch Bio, he held various Business Development and Strategy roles with Karyopharm Therapeutics, where he led business development and corporate strategy efforts. Chris’s experience building global alliances will be instrumental in maximizing Crinetics Pharmaceuticals’ programs and global outreach.

Crinetics is a clinical-stage, publicly traded pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

This executive search was completed by McDermott + Bull Managing Partner Craig Lipus, Partner Garrett Lipus, Directors Tim Dotson and Brian Selvey, and Senior Research Associate Josh Nichols.